IP Library Granted Patent US 10,047,402
Granted Patent B2
US 10,047,402 · App. 14/909,590 · Granted Aug 14, 2018

RASAL1 is a major tumor suppressor gene in thyroid cancer

Inventor: Michael MingZhao Xing (Clarksville, MD)
Assignee: The Johns Hopkins University
C12Q1/6886A61K38/1709C07K14/47C12Q1/68A61K48/00C12Q2600/118C12Q2600/154C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,047,402
App. No.
14/909,590
Granted
Aug 14, 2018
Kind
B2
Abstract

The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for treating thyroid cancer. In certain embodiments, the method comprises the steps of (a) treating DNA isolated from a sample collected from the patient using bisulfite; (b) measuring the DNA methylation level of the promoter region of the RASAL1 gene from the bisulfite-treated DNA using methylation-specific polymerase chain reaction (MSP), wherein the MSP creates a methylation and unmethylation band; (c) normalizing the measured DNA methylation level using an internal reference gene; (d) calculating the percentage of allelic methylation using the formula [M/(M+U]×100%, wherein M and U represent the density of the methylation and unmethylation band; and (e) predicting an increased risk of thyroid cancer in the subject if the percentage of allelic methylation is at least 40%.

Claims (6)

1. A method for predicting an increased risk of thyroid cancer in a patient comprising the steps of:

(a) PCR amplifying exons 13, 14, 15, and 17 of the RASAL1 gene from DNA isolated from a sample collected form the patient to produce a separate PCR product for each of the exons, wherein the amplified products comprise nucleotide 1031 of Exon 13, nucleotides 1153, 1201, 1303, 1312, and 1313 of exon 14, nucleotide 1422 of exon 15, and nucleotide 1782 of exon 17, wherein nucleotide 1 is defined as the A of the ATG translation initiation codon of the RASAL1 gene;

(b) sequencing the PCR amplification products; and

(c) detecting the presence of one or more of a G at position 1031, a T at position 1153, an A at position 1201, a T at position 1303, a T at position 1312, an A at position 1313, an A at position 1422, and an A at position 1782; and

(d) predicting an increased risk of thyroid cancer.

2. The method of claim 1 , wherein the following primers are used for the PCR amplification step: SEQ ID NOS:57-58 for Exon 13; SEQ ID NOS:59-60 for Exon 14, SEQ ID NOS:61-62 for Exon15, and SEQ ID NOS:65-66 for Exon 17.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2018
From: XING, MICHAEL MINGZHAO
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 045621/0714 →
CONFIRMATORY LICENSE Recorded Jun 30, 2016
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039218/0879 →
Continuity (2)
Provisional Application 61861822 · Aug 2, 2013
Related Publication 20160177400A1 · Jun 23, 2016